22nd Century set to try again with very-low-nicotine cigarette Brand A

US biotech company 22nd Century Group has insisted that it plans to resubmit a very-low-nicotine cigarette (VLNC) to the Food and Drug Administration (FDA) by the end of this year, while rebutting criticisms made on an influential investment website.

22nd Century originally filed modified risk tobacco product applications (MRTPs) and premarket tobacco applications (PMTAs) for its “Brand A” product at the end of 2015 but withdrew them a year later.

It said then it had received helpful advice from the FDA, and now it intends to put Brand A forward for approval again.

The product, which is a cigarette made from tobacco but containing “95% less” nicotine than typical combustibles currently on the market, would have to pass through the PMTA process in order to be sold in the US at all.

Successfully completing the MRTP process, which is regarded as much more difficult, would allow Brand A to be marketed overtly as a reduced-risk product.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

View reports

Request a free sample of this report:

“ 22nd Century set to try again with very-low-nicotine cigarette Brand A ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ 22nd Century set to try again with very-low-nicotine cigarette Brand A ”






      US biotech company 22nd Century Group has insisted that it plans to resubmit a very-low-nicotine cigarette (VLNC) to the Food and Drug Administration (FDA) by the end of this year, while rebutting criticisms made on an influential investment website.

      22nd Century originally filed modified risk tobacco product applications (MRTPs) and premarket tobacco applications (PMTAs) for its “Brand A” product at the end of 2015 but withdrew them a year later.

      It said then it had received helpful advice from the FDA, and now it intends to put Brand A forward for approval again.

      The product, which is a cigarette made from tobacco but containing “95% less” nicotine than typical combustibles currently on the market, would have to pass through the PMTA process in order to be sold in the US at all.

      Successfully completing the MRTP process, which is regarded as much more difficult, would allow Brand A to be marketed overtly as a reduced-risk product.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik